EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.
British Journal of Cancer.
Times cited: 12
North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Annals of Oncology.
Times cited: 24